A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice.
The prebiotic Bimuno is a mixture containing galactooligosaccharide, produced by the galactosyltransferase activity of Bifidobacterium bifidum NCIMB 41171 in the presence of lactose. Previous studies have implicated prebiotics in reducing infections by enteric pathogens, thus it was hypothesized that Bimuno may confer some protection in the murine host from Salmonella enterica serovar Typhimurium (S. Typhimurium) infection. In this study, infection caused by S. Typhimurium SL1344nal(r) in the presence or absence of Bimuno was assessed using tissue culture assays, a murine ligated ileal gut loop model and a murine oral challenge model. In tissue culture adherence and invasion assays with HT-29-16E cells, the presence of approximately 2 mM Bimuno significantly reduced the invasion of S. Typhimurium SL1344nal(r) (P<0.0001). In the murine ligated ileal gut loops, the presence of Bimuno prevented colonization and the associated pathology of S. Typhimurium. In the BALB/c mouse model, the oral delivery of Bimuno prior to challenge with S. Typhimurium resulted in significant reductions in colonization in the five organs sampled, with highly significant reductions being observed in the spleen at 72 and 96 h post-challenge (P=0.0002, <0.0001, respectively). Collectively, the results indicate that Bimuno significantly reduced the colonization and pathology associated with S. Typhimurium infection in a murine model system, possibly by reducing the invasion of the pathogen into host cells.
Searle
Laura E J
LEJ
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Best
Angus
A
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Nunez
Alejandro
A
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Salguero
Francisco J
FJ
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Johnson
Linda
L
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Weyer
Ute
U
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Dugdale
Alexandra H
AH
Faculty of Veterinary Science, University of Liverpool, Leahurst, Chester High Road, Neston, Wirral CH64 7TE, UK.
Cooley
William A
WA
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Carter
Ben
B
South East Wales Trials Unit, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Jones
Gareth
G
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
Tzortzis
George
G
Clasado Ltd, 5 Canon Harnett Court, Wolverton Mill, Milton Keynes MK12 5NF, UK.
Woodward
Martin J
MJ
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
La Ragione
Roberto M
RM
Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
D000818:Animals; D001644:Bifidobacterium / Q000201:enzymology*; D005243:Feces / Q000382:microbiology; D005260:Female; D019073:HT29 Cells; D006801:Humans; D007082:Ileum / Q000382:microbiology / Q000473:pathology / Q000648:ultrastructure; D008099:Liver / Q000382:microbiology; D051379:Mice; D009844:Oligosaccharides / Q000627:therapeutic use*; D012480:Salmonella Infections / Q000188:drug therapy* / Q000382:microbiology*; D012486:Salmonella typhimurium / Q000187:drug effects*; D013154:Spleen / Q000382:microbiology
D009844:Oligosaccharides